Actively Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-04-14
20
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate progression-free survival (PFS) of microwave ablation in combination with tislelizumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have progressed following first-line immunotherapy combined with chemotherapy. Participants with advanced NSCLC who experienced disease progression after first-line immunotherapy plus chemotherapy will receive the following treatments: 1. Tislelizumab: 200 mg administered intravenously every 3 weeks (Q3W) 2. Docetaxel: 75 mg/m² administered intravenously every 3 weeks (Q3W) for 4-6 cycles 3. Microwave ablation, administered per protocol
CONDITIONS
Official Title
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC), stage IIIB, IIIC, or IV (AJCC 9th edition) not eligible for curative treatment
- Male or female patients aged 18 years or older who have provided written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with expected survival over 6 months and suitable for microwave ablation
- Prior first-line treatment with tislelizumab combined with chemotherapy and documented disease progression by imaging
- Disease progression occurred 6 months or more after starting first-line tislelizumab plus chemotherapy, with or without anti-angiogenic therapy
- Adequate organ and bone marrow function as defined by specific blood count and liver, kidney, and coagulation test values
- Cardiac function with left ventricular ejection fraction (LVEF) of 50% or higher
- Ability to communicate effectively and comply with study visits, treatment, and tests
You will not qualify if you...
- Diagnosis of small cell lung cancer (SCLC) or mixed small cell and non-small cell lung cancer
- Symptomatic brain metastases at the start of treatment
- Concurrent participation in another interventional cancer treatment trial
- History of tracheoesophageal fistula, gastrointestinal perforation, fistula, or intra-abdominal abscess within 6 months prior to treatment
- Severe cardiovascular or cerebrovascular disease within 6 months prior to randomization, including stroke, heart attack, unstable angina, heart failure (NYHA class II or higher), or significant ECG abnormalities
- Major surgery within 4 weeks prior to enrollment or planned during the study
- Bleeding disorders, high bleeding risk, recent thrombotic events within 6 months, or hemoptysis within 3 months prior to randomization
- Presence of unhealed wounds, active gastrointestinal ulcers, or fractures (except healed fractures)
- Known or suspected allergy to tislelizumab or its components
- Pregnant or breastfeeding women
- Women of childbearing potential or men unwilling to use effective contraception during the study and for 6 months after last treatment
- Any condition that the investigator considers makes the participant unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China, 300308
Actively Recruiting
Research Team
T
Tongguo Si, MD. Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here